INT270322

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 2.08
Pain Relevance 0.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (PDZD2) cell adhesion (PDZD2) endoplasmic reticulum (PDZD2)
nucleus (PDZD2) cytoplasm (PDZD2)
PDZD2 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 2 99.30 Very High Very High Very High
Pain 9 90.84 High High
addiction 5 10.16 Low Low
palliative 1 5.00 Very Low Very Low Very Low
dexamethasone 1 5.00 Very Low Very Low Very Low
Somatostatin 1 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Serotonin 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Prostate Cancer 79 100.00 Very High Very High Very High
Disease Progression 2 94.80 High High
Metastasis 9 92.76 High High
Osteoporosis 2 92.12 High High
Pain 9 90.84 High High
Apoptosis 4 89.32 High High
Cancer 27 76.72 Quite High
Toxicity 2 72.92 Quite High
Death 7 55.04 Quite High
Leukemia 1 43.04 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
AIPC is characterized by androgen action in the absence of androgen stimulation.
Regulation (characterized) of AIPC associated with prostate cancer
1) Confidence 0.10 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2812491 Disease Relevance 1.18 Pain Relevance 0
A large phase III trial with single-agent atrasentan (Abbott Laboratories), an oral ETA receptor antagonist, was stopped early due to lack of efficacy in AIPC.[25] However in a preliminary report of a metaanalysis, AIPC patients treated with atrasentan were 14% less likely to experience disease progression (HR = 0.86, 95% CI 0.75-0.99), had an 18% less likelihood of experiencing bony pain (HR = 0.82, 95% CI 0.69-0.98) and had a 22% less chance of experiencing PSA progression (HR = 0.78, 95% CI 0.69-0.98).[26] This has given rise to a randomized trial under way through the SWOG 0421, which compared docetaxel plus atrasentan vs. docetaxel alone for AIPC.
Regulation (efficacy) of AIPC associated with pain, antagonist, prostate cancer and disease progression
2) Confidence 0.01 Published 2008 Journal Indian Journal of Urology : IJU : Journal of the Urological Society of India Section Body Doc Link PMC2684340 Disease Relevance 0.89 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox